Results 221 to 230 of about 47,532 (242)

Subjective Olfactory Impairment in a Patient Undergoing Anti-Obesity Pharmacotherapy: A Case of Symptom-Test Discrepancy. [PDF]

Life (Basel)
Lee HJ, Min HJ.
europepmc   +1 more source

Cryo-EM Structures Reveal Key Mechanisms of Noradrenaline Transporter. [PDF]

MedComm (2020)
Su P, Li M, Zhou F.
europepmc   +1 more source

Naltrexone-induced skin lesions in a patient with alcohol use disorder.

Ind Psychiatry J
Rikhari P, Chaubey AN.
europepmc   +1 more source

Risk of Major Congenital Malformations Following Prenatal Exposure to Smoking Cessation Medicines.

JAMA Intern Med
Tran DT, Cohen JM, Donald S, Cesta CE, Furu K, Parkin L, Pearson SA, Reutfors J, Robijn AL, Zoega H, Zwar N, Havard A.   +11 more
europepmc   +1 more source

Treatment Response to Bupropion: An Investigation of Changes in Resting-State Functional Connectivity in Patients with Major Depressive Disorder

Klonteig SE, Walsh AEL, Jonassen R, Browning M, Harmer CJ, Martens MA.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.

American Journal of Psychiatry, 2022
OBJECTIVE Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to
H. Tabuteau, A. Jones, Ashley Anderson, M. Jacobson, D. Iosifescu   +4 more
semanticscholar   +1 more source

Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses

Obesity Reviews, 2021
Despite being approved for clinical use, evidence of cardiovascular safety (CV) is lacking for treatment with bupropion, naltrexone, or their combination (B‐N).
A. Sposito, I. Bonilha, B. Luchiari, A. Benchimol, Alexandre Hohl, Fabio Moura, C. Cercato, B. Geloneze, W. Nadruz, C. Aguilar-Salinas, L. F. Carvalho   +10 more
semanticscholar   +1 more source

Serotonin toxicity from isolated bupropion overdoses

Clinical toxicology, 2020
Background: Bupropion is a synthetic cathinone, which acts therapeutically through norepinephrine and dopamine reuptake inhibition. Recent evidence suggests that serotonin receptor activation occurs with high doses of bupropion and severe serotonin ...
A. Sidlak, Karl O Koivisto, R. Marino, Michael G. Abesamis   +3 more
semanticscholar   +1 more source